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Background: The Streptococcus pneumoniae sialidase NanC produces a nonspecific inhibitor of hydrolytic sialidases.
Results: The NanC crystal structure is presented in complex with mechanistically relevant ligands.
Conclusion: A constricted and hydrophobic active site produces 2-deoxy-2,3-didehydro-N-acetylneuraminic acid
(Neu5Ac2en, also known as DANA) via a covalent intermediate and direct proton abstraction by a catalytic aspartic acid.
Significance: Insights into an unusual reaction mechanism will aid the design of sialidase inhibitors.
Streptococcus pneumoniae is an important human pathogen
that causes a range of disease states. Sialidases are important
bacterial virulence factors. There are three pneumococcal siali-
dases: NanA, NanB, and NanC. NanC is an unusual sialidase in
that its primary reaction product is 2-deoxy-2,3-didehydro-N-
acetylneuraminic acid (Neu5Ac2en, also known as DANA), a
nonspecific hydrolytic sialidase inhibitor. The production of
Neu5Ac2en from 2–3-linked sialosides by the catalytic
domain is confirmedwithin a crystal structure. A covalent com-
plex with 3-fluoro--N-acetylneuraminic acid is also presented,
suggesting a commonmechanismwith other sialidases up to the
final step of product formation. A conformation change in an
active site hydrophobic loop on ligand binding constricts the
entrance to the active site. In addition, the distance between the
catalytic acid/base (Asp-315) and the ligand anomeric carbon is
unusually short. These features facilitate a novel sialidase reac-
tion in which the final step of product formation is direct
abstraction of the C3 proton by the active site aspartic acid,
formingNeu5Ac2en. NanC also possesses a carbohydrate-bind-
ing module, which is shown to bind 2–3- and 2–6-linked
sialosides, as well asN-acetylneuraminic acid, which is captured
in the crystal structure following hydration of Neu5Ac2en by
NanC. Overall, the pneumococcal sialidases show remarkable
mechanistic diversity while maintaining a common structural
scaffold.
TheGram-positive bacterium Streptococcus pneumoniae is a
common resident of the human nasopharynx. Although car-
riage is normally asymptomatic, the bacterium can cause severe
illness, particularly in the very young, the elderly, and the
immunocompromised, and canbe triggered following infection
with the influenza virus (1, 2). S. pneumoniae is amajor cause of
bacterial meningitis (3), themost frequent cause of otitis media
and sepsis in children, and the primary cause of community-
acquired and hospital-acquired pneumonia in adults (4). Con-
jugate vaccines have successfully targeted the most prevalent
strains (5, 6). However, the disease burden rebounds because of
replacement disease caused by strains not included in the vac-
cine (7–9). Furthermore, the search for novel therapeutics
against S. pneumoniae is becoming more pertinent in view of
decreasing antibiotic efficacy because of increased prevalence
of single and multidrug-resistant strains (10, 11).
Pneumococcal sialidases are implicated in host colonization
and pathogenesis (12). They facilitate invasion through desia-
lylation of the host cell surface decrypting sites for bacterial
adhesion (13) and promote biofilm formation (14). The carbo-
hydrate-binding module (CBM)5 associated with the NanA
sialidase has been shown to be involved in cell surface binding
and invasion of the blood-brain barrier (15). Finally, the release
of sialic acid fromhost cells by pneumococcal sialidases has also
been proposed as an important source of both carbon and
energy (16).
Sialidases show promise as targets for both vaccines and
small molecule inhibitors (17–19). The latter strategy has
already been adopted and proven successful against the influ-
enza virus (20). S. pneumoniae produces up to three distinct
sialidase enzymes: NanA, NanB, and NanC. Among 342 pneu-
mococcal strains, the nanA, nanB, and nanC genes were pres-
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ent in 100, 96, and 51% of isolates, respectively, with signifi-
cantly higher nanC prevalence in cerebrospinal fluid isolates in
comparison with carriage isolates from the upper respiratory
tract (21). More recently, the nanC gene was found to have an
increased occurrence in isolates from children with haemo-
lytic-uraemic syndrome compared with non-haemolytic urae-
mic syndrome controls (22).
The crystal structures for NanA and NanB are available and
show domain conservation: a signal sequence, an N-terminal
carbohydrate-binding module, and a catalytic -propeller
domain with an irregular inserted (I) domain of unknown func-
tion that protrudes from the catalytic domain (23–26). NanC
shares 25% sequence identity with NanA and 51% sequence
identity with NanB. NanB and NanC are of similar size, 78 and
82 kDa, respectively. NanA is largest at 115 kDa because of the
presence of a C-terminal membrane-anchoring domain.
The pneumococcal sialidases vary in substrate specificities,
mechanism, and kinetic parameters. Although NanA can
cleave a range of sialic acid substrates including those with
2–3, 2–6, and 2–8 glycosidic linkages (23, 27), NanB and
NanC have specificity for 2–3-linked substrates (24, 25, 27).
NanA is a typical exo or hydrolytic sialidase, hydrolyzing its
substrates to releaseN-acetylneuraminic acid (Neu5Ac). NanB
is an intramolecular trans-sialidase generating 2,7-anhydro-
Neu5Ac as a reaction product (24, 25). Despite the high
sequence similarity to NanB, NanC has been shown to differ in
that it initially generates Neu5Ac2en, a molecule that inhibits
NanA with a Ki of 2 M (24, 28). In fact, Neu5Ac2en appears
to be a nonspecific inhibitor of hydrolytic sialidaseswithmicro-
molar inhibition also observed against influenza virus
neuraminidase (29), the human sialidases (30, 31), and VcNA
fromVibrio cholerae (32).Neu5Ac2en is a very poor inhibitor of
NanC with a Ki of 2–3 mM (27, 28). Following depletion of the
2–3-linked substrate, NanC can hydrate Neu5Ac2en to
Neu5Ac (27). Here we present the crystal structure of NanC
and its catalytic active site complexes with the reaction product
Neu5Ac2en, a covalently bound reaction intermediate, 3-
fluoro--N-acetylneuraminic acid (3F--Neu5Ac), and the
viral neuraminidase inhibitor oseltamivir carboxylate (OC). In
addition, complexes with the substrate 2–3-sialyllactose
(3SL), 2–6-sialyllactose (6SL), and Neu5Ac in the CBM
binding site of the catalytic domain are described. Together,
these data provide a structural basis for the unusual production
of Neu5Ac2en by this enzyme.
Experimental Procedures
Coordinates for all crystal structures have been deposited in
the Protein Data Bank. Two separate cloning, expression, and
purification schemes were used. PDB codes 4YW0, 4YW1,
4YW2, 4YW3, and 4YW5 were obtained from scheme A, and
PDB codes 4YZ1, 4YZ2, 4YZ4, and 4YZ5 were obtained from
scheme B as described below. Differences between the two
schemes will be highlighted and referred to as A or B through-
out the methods description.
Cloning—For A, the S. pneumoniae TIGR4 nanC gene was
expressed in the pet21b vector (28). The construct encom-
passed residues 28–740. For B, genomic DNA purified from
S. pneumoniae TIGR4 (kindly supplied by Dr. Samantha King,
Nationwide Children’s Hospital, Columbus, Ohio) was used as
a template for PCR amplification of the NanC protein-coding
region. The In-Fusion cloning method was used to insert the
PCR product into a pOPINF plasmid vector (33). The final con-
struct encompassed residues 83–740.
Expression and Purification—Recombinant plasmids (A and
B) were expressed in Escherichia coli Rosetta (DE3) expression
strain (Novagen) in autoinduction media (A, Formedium; B,
Overnight Express TB autoinduction media from Novagen).
The cultures were initially grown at 37 °C, followed by pro-
longed growth at lowered temperatures (A, 200 rpm, 60 h,
16 °C; B, 230 rpm, 20 h, 25 °C). The cells were harvested by
centrifugation, resuspended in lysis buffer (A, 20 mMTris-HCl,
pH7.5, 50mMNaCl, 5mM imidazole; B, 50mMTris, pH 7.5, 500
mM NaCl, 30 mM imidazole, pH 7.5, 0.2% Tween 20, 5% w/v
glycerol) supplementedwithDNase I (10–20g/ml) andCom-
plete protease inhibitor mixture tablets (Roche), and lysed
using a constant flow cell disrupter. Insoluble componentswere
removed by centrifugation. Soluble lysate was loaded onto
nickel-Sepharose columns (GE Healthcare) equilibrated in (B,
Tween 20-free) lysis buffer. Bound protein was washed exten-
sively using lysis buffer (A, containing 20 mM imidazole; B,
excluding Tween 20) and eluted using an imidazole step gradi-
ent (A, lysis buffer containing 60 mM imidazole; B, lysis buffer
containing 500 mM imidazole and excluding Tween 20).
In scheme A, the eluted protein fraction was diluted 1:2 with
20 mM Tris-HCl, pH 7.5, and loaded onto a 5-ml SP-FF cation-
exchange column (GE Healthcare). The bound protein was
washed using 20mMTris-HCl, pH 7.5, 100mMNaCl and eluted
using 20 mM Tris-HCl, 300 mMNaCl. The major peak from (A,
cation-exchange; B, nickel affinity purification) was concen-
trated and subjected to size exclusion chromatography using a
120-ml Sephacryl S-200 column (GE Healthcare) equilibrated
in 20 mM Tris, pH 7.5 (A) or 20 mM Tris, pH 7.5, 200 mMNaCl,
5% glycerol (B). In scheme B, post size exclusion, the protein
was subjected to His6 tag cleavage by incubation with 0.1%
(w/w) human rhinovirus B 3C protease (14 h, 4 °C), followed by
reverse His tag purification.
Protein Crystallization—Promising crystals were obtained
from 16% PEG8000, 20% glycerol, 40 mM KH2PO4 at 20 mg/ml
(A) and 20% PEG3350, 0.25 M ammonium sulfate, 0.1 M Hepes,
pH8.0, at 10mg/ml (B). These initial crystals were optimized by
varying crystallization droplet size and protein to precipitant
ratio (A, 1l 7.5mg/ml protein, 2l of reservoir solution, 0.5l
of seed stock; B, 0.5 l of 10 mg/ml protein, 0.5 l of reservoir),
incorporation of additives (A, 10% degassed sugar-free Irn-Bru
(A.G. Barr); B, 7.5% ethanol or isopropanol), and microseeding
(A) (34). Additives were critical in increasing crystal thickness.
To prepare derivative crystals, ligands were individually added
to the reservoir solution to a concentration of 5–200 mM.
Native crystals were then soaked in the solution for 2–45 min.
Scheme B crystals were then transferred into a cryoprotectant
solution consisting of the reservoir solution, 100–200 mM of
the same ligand, and 20% (v/v) ethylene glycol. Additional cryo-
protectant was not necessary for scheme A crystals.
X-ray Diffraction, Data Collection and Processing—Crystal-
lographic data were collected at various locations (A, Beamline
ID23-2 European Synchrotron Radiation Facility and in-house
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Rigaku 007HFM rotating anode x-ray generator with a Saturn
944 CCD detector; B, Beamline I04, Diamond Light Source
synchrotron). Data collected in-house were reduced using the
HKL2000 package (35). Synchrotron data were processed by
the xia2 automated reduction system (36) which makes use of
Mosflm (37), Pointless (38), CCP4 (39), and XDS (40). Struc-
tures were solved by PHASER molecular replacement (41)
using the S. pneumoniae NanB structure (PDB code 2VW2
(24)) as the search model. The initial models were autobuilt by
ARP/wARP (42) and improved by iterative cycles of manual
rebuilding in Coot (43) and refinement in Refmac5 (44) (A and
B) and Buster-TNT (45) (B). The PDB_REDO (46) andMolPro-
bity (47) servers were used to inform the refinement and for
structure validation. Statistics for data collection and refine-
ment are listed in Table 1.
Isothermal TitrationCalorimetry—TheNanCCBMwas sub-
cloned into the pEHISTEV vector using primers GGCGCCA-
TGGCTCAGGAGACTGAAACTTCTG and TGGTGCTCG-
AGTTTACATCTTTTTAACAGTTTCTTC and purified
according to scheme A with the addition of His6 tag cleavage
using TEV protease and reverse His tag purification (48). ITC
experimentswere performed using aVP-ITCmicrocalorimeter
(MicroCal Inc.) with a cell volume of 1.54 ml. Prior to titration,
protein sampleswere exhaustively dialyzed into 20mMTris, pH
8, 50 mM NaCl. The ligand was dissolved in the dialysis buffer.
Analysis was performed using nonlinear regression and a single
binding site model within MicroCal Origin software (version
7.083). Heat of dilution experiments were performed, and the
resulting isotherm was subtracted from the experimental
conditions.
Results
Overall Structure—NanCadopts the sameoverall topology as
seen in NanA and NanB, with a CBM (residues 85–271), fol-
lowed by a catalytic domain (residues 272–740; Fig. 1a). The
CBM presents a CBM family 40 (CBM40) -sandwich fold (49)
with six-antiparallel strands forming a convex surface and five
strands forming a concave, carbohydrate-binding side. The cat-
alytic domain adopts the canonical glycoside hydrolase family
33 sialidase, six-bladed-propeller fold (Fig. 1b) shared by viral,
bacterial, and mammalian sialidases. Asp boxes, motifs typical
of bacterial sialidases (50), are present in four of the-propeller
blades. Protruding from the catalytic domain is an I domain
comprised mainly of -strands (residues 403–498). I domains
are present in the other pneumococcal sialidases (23–25, 51), as
well as NanI from Clostridium perfringens (52), NanL from
Macrobdella decora (53), and NanH from Ruminococcus gna-
vus (54). However, I domains are not a general feature of siali-
dases; for example, they are absent fromVcNA fromV. cholerae
(55),Neu2 fromHomo sapiens (56), andNedA fromMonospora
viridifaciens (57). The function of I domains remains unknown.
The absent N-terminal residues include a signal sequence (res-
idues 1–27) that was deleted to aid structural studies and a
short region of unknown function (residues 28–84) of which
electron density was only observed for residues 83 and 84.
NanC-CBM Complexes—Structures of the CBM have been
obtained in complex with Neu5Ac, 3SL, and 6SL (Figs. 2a and
3, a–i) Neu5Ac complexes were achieved by soaking NanC
crystals with Neu5Ac and also by extended soaks (20 min)
with Neu5Ac2en, thus confirming that NanC can hydrate
Neu5Ac2en to Neu5Ac. Following short soaks (2 min) with
3SL and soaks with 6SL, electron density was observed for the
sialyl and galactosyl rings; the glucosyl rings were not visible in
electron density. Key interacting residues of the CBM binding
site areArg-237 andArg-161, which provide electrostatic inter-
actions with the Neu5Ac carboxylate group; Glu-159, which
hydrogen bonds to the O4 hydroxyl group; and Arg-151, which
hydrogen bonds to the carbonyl of theN-acetyl group (Figs. 2, a
and d, and 3, b and c). In addition, Phe-149, Leu-128, and Leu-
170 form a hydrophobic pocket that accommodates the termi-
nal methyl of the N-acetyl group. Observed protein to ligand
interactions are limited to the terminal Neu5Ac residue. Thus
the affinities of 3SL and 6SL for the NanC CBM were very
similar, with Kd values of 1.48 mM (Fig. 2b) and 1.60 mM (Fig.
2c), respectively, as measured by isothermal titration calorime-
try (ITC). The binding site of theCBM is on the same side as the
active site of the catalytic domain and the protein face onwhich
they reside displays an overall positive charge (Fig. 1, b and c).
These two factors combined could have a role in orienting the
active site in relation to the negatively charged host-bound
substrate.
The NanC Active Site—Structures of NanC have been deter-
mined with Neu5Ac2en, 3F--Neu5Ac, and OC bound at the
catalytic active site (Fig. 3, c–f, h, and i). The NanC active site is
a narrow constricted cleft, similar toNanB (24, 25) and contrary
to NanA (23, 26). A primary component of this constriction is
the hydrophobic stack of Trp-716 and Tyr-632 (Fig. 4a). These
residues partially block the active site entrance providing spec-
ificity for 2–3-linked substrates as opposed to 2–6.
Soaking NanC crystals with 3SL traps Neu5Ac2en in a half-
chair conformation in the active site (Figs. 3, c and d, and 4a).
The negatively charged active site shares key features of struc-
turally characterized bacterial, mammalian and parasitic siali-
dases in general and the pneumococcal sialidases in particular
(23–26, 52–59). Thus, many of the Neu5Ac2en to NanC inter-
actions are also conservedwithNanAandNanB (Fig. 4, b and c).
These include an arginine triad, comprised of Arg-290, Arg-
600, and Arg-662, which orients the ligand in the active site via
electrostatic interactionswith theNeu5Ac2en carboxylate (Fig.
4, a and b). The hydrophobic pocket (comprised of Ile-371,
Met-390, Phe-316, and Phe-396) accommodates the N-acetyl
groupmirroring theCBM.The ligand sits on top of the catalytic
pair of Glu-584 and Tyr-695 and beneath the general acid base
Asp-315. The latter residue is substantially closer to the C2 of
Neu5Ac2en than in NanA or NanB Neu5Ac2en complexes: 3.2
Å in comparison with 4.2 and 4.5 Å, respectively (Fig. 4d; Refs.
23 and 24). Other interacting residues include Ser-582, which is
within hydrogen bonding distance of terminal hydroxyls of the
Neu5Ac2en glycerol moiety. Arg-309 forms a hydrogen bond
with the C4 hydroxyl. Asp-372 forms hydrogen bonds with
both the C4 hydroxyl and N5 of the N-acetyl moiety.
Formation of a Covalent Intermediate in the Active Site—
NanC crystals soaked with 2,3-difluoro-N-acetylneuraminic
acid (2,3F-Neu5Ac) presented continuous electron density
from the ligand C2 position to Tyr-695 (Fig. 5, a and b). 3F--
Neu5Ac was covalently bound to Tyr-695 in an unstrained 2C5
Structural Insights into NanC: the Third Streptococcus Sialidase
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chair conformation. Equivalent complexes have also been
observed in theC. perfringens sialidase NanI, the Trypanosoma
rangeli sialidase TrSA, and the Trypanosoma cruzi trans-siali-
dase TcTS (52, 60, 61). The covalent bond distance is 1.9 Å (Fig.
5a). 2,3F-Neu5Ac was also found bound in the CBM binding
site (Fig. 3h).
Plasticity in Active Site 396 Loop—The most significant
structural change observed upon binding and/or formation of
Neu5Ac2en is the substantial shift in Phe-316 and Phe-396 of
the hydrophobic pocket and the loop upon which the latter
resides (herein named the 396 loop, residues 392–401) (Fig.
6a). The C of Phe-396 advances 2.1 Å into the active site, and
the side chain changes conformation, moving out of the active
site to accommodate the ligand.Thenet result of themovement
of the 396 loop is that it partially constricts the active site (Fig. 6,
b and c). The movement appears to be stabilized by hydropho-
bic interactions between Phe-396 and the C9 carbon of
Neu5Ac2en because no hydrogen bonds or other stabilizing
interactions are formed between the residues of the 396 loop
and Neu5Ac2en (Fig. 6a).
Although a poor inhibitor (28), OC binds in the NanC active
site (Figs. 3i and 7, a and b). Compared with Neu5Ac2en, OC
undergoes a translation of0.8 Å, along a plane approximately
FIGURE 1. a, NanC domain organization and the amino acid boundaries are
shown,with theCBM in light blue, the sialidase catalytic domain in yellow, and
the inserted domain in pink. b, in the cartoon representation the bound
ligands, Neu5Ac2en in the catalytic domain, and 3SL in the CBM (PDB code
4YZ5) are shown as spheres. c, an electrostatic surface has been applied to the
unbound crystal structure (PDB code 4YZ1) with the catalytic domain active
site and the CBM binding site indicated with arrows 1 and 2, respectively.
Electrostatic potentials (units of kT/e from10 to10)were calculatedbyAPBS
(76) and visualized on the solvent-accessible surface by the program PyMOL
(77).
FIGURE 2. a, the CBM binding site of NanC (light blue) with superimposed
bound 3SL (yellow; PDB code 4YZ5) and 6SL (green; PDB code 4YW2)
molecules shown with selected interacting residues. Dashed black lines
indicate hydrogen-bonding interactions and a semitransparent surface
(orange) applied to Leu-128, Phe-149, and Leu-170 indicates the hydro-
phobic pocket. b and c, ITC experiments assessing the binding of 3SL and
6SL, respectively, to subcloned NanC CBM. Based on crystallographic evi-
dence, the binding curve was calculated using a fixed substrate to binding
site stoichiometry of 1:1. For 3SL binding constant K  677  7.44 M1,
	H11.4 0.078 kcal/mol, T	S7.54 kcal/mol corresponding to a
Kd of 1.48 mM. 
2/DoF  92.49. For 6SL binding constant K  626  4.43
M
1, 	H 8.09 0.036 kcal/mol, T	S4.26 kcal/mol corresponding to
a Kd of 1.60 mM. 
2/DoF  16.78. d, a schematic representation of the
interactions between Neu5Ac and the CBM binding site (PDB code 4YW1)
visualized using Poseview (78).
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defined by the ligand ring, out of the active site. This is likely to
be caused by the electrostatic repulsion between the 4-amino
group of OC and Arg-309. In comparison with the Neu5Ac2en
complex, arginine triad interactions, and hydrogen bonds from
Asp-372 to both the 4-amino group and the N-acetyl amine
group are maintained. The 4-amino group induces a pivot in
Asp-315 introducing a new hydrogen-bonding partner. The
Neu5Ac2en interactions with Ser-582 andTyr-553 via the glyc-
erol group are lost. Furthermore, the Neu5Ac2en glycerol
group makes favorable hydrophobic interactions with Phe-396
(Fig. 6a), whereas theOC pentyl ether group is unable to repro-
duce this interaction, and the 396 loop does not move into the
FIGURE 3. Views of the CBM binding site (light blue) and catalytic domain active site (AS, yellow) for all described crystal structures. Bound ligands
(green) are indicated for both sites. Soaking ligandswere: none PDB code 4YZ1 (a), 6SL PDB code 4YW2 (b), 3SL (200mM for 2min) PDB code 4YZ5 (c), 3SL (20
mM for 15min) PDB code 4YW1 (d), Neu5Ac2en (50mM for 2min) PDB code 4YZ2 (e), Neu5Ac2en (20mM for 45min) PDB code 4YW3 (f), Neu5Ac PDB code 4YZ4
(g), 2,3F-Neu5Ac PDB code 4YW0 (h), and OC PDB code 4YW5 (i). The Fo Fc omit map electron density is shown carved around the ligands and contoured at
a level of 3  (magenta mesh). Panels a–i correspond to crystal structures a–i in Table 1.
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active site (Fig. 7a). This is predicted to be due to steric clashing
between Phe-396 and the pentyl group.
Discussion
NanC is an unusual sialidase in that its primary reaction
product is Neu5Ac2en, a nonspecific sialidase inhibitor. We
have captured crystal structures of the catalytic site of NanC in
complexwith its first product,Neu5Ac2en (Fig. 3d), and a cova-
lent intermediate using a fluorinated substrate analogue (Fig.
3h) and the influenza viral neuraminidase inhibitorOC (Fig. 3i).
In addition, we have captured complexes of the CBM with
Neu5Ac, 3SL, and 6SL (Fig. 3, g, c, and b).
The Proposed NanC Reaction Mechanism—The presented
crystal structures provide insight into the NanC reaction spec-
ificity and mechanism. Following substrate selection, the sub-
strate is orientated through electrostatic interactions between
the Neu5Ac carboxylic acid and the arginine triad. This brings
the C2 position into proximity with Tyr-695, which can per-
FIGURE 4. Neu5Ac2en binding. a, the NanC active site (yellow) is shown with Neu5Ac2en (green) bound (PDB code 4YW3). Predicted hydrogen bonding
interactions are shownwith black dashed lines. A hydrophobic interaction between the C9 and Phe-396 is indicatedwith green and blue spheres (Van derWaals
contacts generated using PROBE (79)). The hydrophobic stack providing specificity for 2,3-linked substrates is highlighted with a semitransparent gray
surface. b, a schematic representation of the interactions between Neu5Ac2en and the active site. c, for comparison the active sites of NanA (blue) and NanB
(purple) are alignedontoNanC.d, a close-upviewof thedistances inÅbetween theNeu5Ac2enanomeric carbonandconservedacidbase aspartic acid. e, three
orientations of the bound Neu5Ac2en ligand are shown. The Fo  Fc omit electron density map is contoured at sigma levels of 3 (cyan), 5 (orange), and 7
(magenta) carved at a distance of 1.6 Å.
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form a nucleophilic attack. This step appears to be common to
all three pneumococcal sialidases (27). Tyr-695 was confirmed
as the nucleophile by soaking a NanC crystal with 2,3F-
Neu5Ac, capturing a sialyl-enzyme intermediate with 3F--
Neu5Ac covalently bound to Tyr-695. The electronegative flu-
orine atoms at positions C2 and C3 allow trapping of the
covalent intermediate by respectively providing a good leaving
group and destabilizing the formation of the positive charged
transition state required for enzyme desialylation (62). At this
point in a classical hydrolytic sialidase, such as NanA, the inter-
mediate would undergo nucleophilic attack by an activated
water molecule at the C2 anomeric carbon, releasing Neu5Ac
(Fig. 8). However, when NanC crystals were soaked with 3SL,
Neu5Ac2en is found in the active site. Thus we propose that
Asp-315 abstracts the proton directly from the C3 position,
eliminating Tyr-695 and forming Neu5Ac2en (Fig. 8a).
When the pool of substrate is exhausted andNeu5Ac2en is in
excess, NanC can hydrate Neu5Ac2en to Neu5Ac.When short
3SL soaks are performed, electron density is observed for
uncleaved 3SL in the CBMbinding site withNeu5Ac2en in the
active site (Fig. 3c). When longer soaks were performed,
Neu5Ac2en is still observed in the active site, and cleaved
Neu5Ac was observed in the CBM binding site (Fig. 3d). When
short Neu5Ac2en soaks were performed, the CBM binding site
was empty, whereas boundNeu5Ac became apparent when the
soaking time was increased. This is consistent with 1H NMR
experiments where Neu5Ac2en is formed after 0.5 h and is
hydrated to Neu5Ac over a further period of 6 h (27). During
Neu5Ac2en hydration to Neu5Ac, there would not be a leaving
glycan preventing solvent access to the ligand C2 position,
allowing the hydration reaction to proceed via the mechanism
described for the C. perfringens sialidase NanI by Newstead
et al. (27, 52). In short, the nucleophilic electrons in the
Neu5Ac2en -bond attack the nearby Asp-315 proton. This
generates a delocalized positive charge at the ligand C2 posi-
tion, stabilized by Tyr-695 and vulnerable to nucleophilic
attack by an activated water molecule, resulting in the forma-
tion of Neu5Ac (Fig. 8b).
FIGURE 5. a, 3F--Neu5Ac covalently bound in theNanC active site (PDB code
4YW0). The Fo  Fc omit map electron density map is carved around the
ligand and Tyr-695 and contoured at a level of 3  (magenta mesh). b, a sche-
matic representationof the interactions between3F--Neu5Ac and theNanC
active site.
FIGURE6.Structural perturbations in thehydrophobic loop.a, the occlud-
ing 396 loop position, when in complex with Neu5Ac2en, is shown in yellow
(PDB code4YW0). Thenonoccluding loopposition, in theunboundactive site
of the apo-structure, is shown in purple (PDB code 4YZ1). The distance
between the Phe-396 C carbons in the two conformations is 2.1 Å.
Neu5Ac2en is shown in green. Spheres represent the favorable hydrophobic
interactions between Phe-396 and Neu5Ac2en. b and c, a solvent-accessible
surface has been applied to the nonconstricted and constricted conforma-
tions, respectively. The position of the Phe-396 residue is highlighted by a
light green surface.
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Reaction Determinants—The NanC active site is similar to
that of other sialidases. However, there are important differ-
ences. First, Asp-315 is 1 Å closer to the C2 of Neu5Ac2en
than the equivalent residue in NanA and NanB (Fig. 4d). This
advanced position would allow the C3 proton to be abstracted
directly. In NanA and NanB, there is space for attack at the C2
position by an activated water molecule forming Neu5Ac, and
the C6 glycerol moiety forming 2,7-anhydro-Neu5Ac, respec-
tively, which is not the case in NanC. Mutation of Asp-315 to
Ala abolishes catalytic activity (27).
The data presented here also highlight plasticity in the
hydrophobic 396 loop. Upon binding to Neu5Ac2en, Phe-396,
at the loop apex, is brought into proximity of the ligand by loop
movement (Fig. 6a). This conformational change is a key fea-
ture because themovement constricts the opening to the active
site in a manner that would make it almost watertight (Fig. 6c).
Mutating NanC Phe-396 to the hydrophilic Asn, as is found in
NanB, leads to the production of a mixture of both Neu5Ac2en
andNeu5Ac (27). TheTrp-716 hydrophobic stack and the leav-
ing aglycone groupwould further excludewater from the active
site. This desolvated environment would promote attack by
Asp-315 on the C3 proton. Striking active site loopmovements
have also been observed in the influenza virus neuraminidases
(63) and the human sialidase Neu2 (56).
Enzyme Specificity—The affinities of theNanCCBM for 3SL
and 6SL are similar, at 1.48 and 1.60 mM, respectively (Fig. 2, b
and c). The V. cholerae sialidase also has a sialic acid binding
CBM; however, the affinities for 3SL and 6SL are much
tighter, at 18 and 19M, respectively (64). TheV. choleraeCBM
is proposed to be part of a second CBM40 subfamily (49). Low
affinity could imply that NanC occupies a substrate-rich envi-
ronment. Analogously, the tight affinity of the V. cholerae
CBM40 may suggest a requirement to withstand forces in the
gut that are absent in the NanC niche. In contrast to the less
specific CBM, strict active site specificity for the 2,3-glyco-
sidic linkage is achieved via constriction of the entrance by a
hydrophobic stack of Trp-716 and Tyr-632 (Fig. 4a). This has
also been seen in the intramolecular trans-sialidases NanB (24,
25) andM. decoraNanL (53). In the human respiratory system,
2,3-glycosidic linkage preference would make NanC more
active in the lungs rather than the upper respiratory tract,
which primarily expresses 2–6-linked sialosides (65). Con-
trasting specificity profiles are also observed for the character-
ized human sialidases, with the most broadly and highly
expressed sialidase, Neu1, presenting the widest substrate
range (66).
NanC encoding pneumococcal strains are over-represented
in invasive isolates fromhuman cerebral spinal fluid in compar-
ison with noninvasive isolates from the nasopharynx (21). The
CNS is rich in NanC substrate molecules with 2–3-linked sia-
loglycans found throughout, with amultitude of functions (67).
Parker et al. (68) identified contributions to NanC reaction
selectivity from components of the leaving group. In particular,
NanC cleaved2–3-linked sialyl-LacNAcmore effectively than
2–3-linked sialyl-lactose. 2,3-Linked sialyl-LacNAc is pres-
ent in GD1a and GT1b gangliosides, which account for 25 and
18% of human brain gangliosides, respectively. Residues in the
vicinity of the leaving group that could contribute to this selec-
tivity include Arg-397, Arg-718, and Trp-716. Finally, NanC
does not cleave N-glycolylneuraminic acid containing sialo-
sides (68). Like in the CBMbinding site, the active site holds the
ligand N-acetyl group in a hydrophobic pocket, which would
preclude accommodation of Gc-containing ligands. Humans
have lost the ability to synthesize N-glycolylneuraminic acid,
although it is expressed in many non-humanmammals includ-
ing non-humanhominids such as chimpanzees, bonobos, goril-
las, and orangutans (69). DietaryN-glycolylneuraminic acid can
be incorporated into human glycoproteins (70); however, it
does not access the CNS (71). Although it has been linked to
haemolytic-uraemic syndrome (22), the role of NanC in pneu-
mococcal disease is as yet not understood. The over-represen-
tation of NanC in invasive isolates and CNS isolates and adap-
tation to ligands abundant in the CNS suggest that it may have
an important role in pathogenesis of invasive pneumococcal
disease such as bacterial meningitis.
Oseltamivir Carboxylate Binding—OC is an antiviral agent
designed to target the influenza virus neuraminidase. It has also
demonstrated efficacy against S. pneumoniae infections of the
respiratory tract (72, 73). NanA is inhibited by OC with a Ki of
1.77 M, whereas no effective inhibition is observed against
FIGURE 7. a, OC bound in the NanC active site (PDB code 4YW5, salmon) in
comparisonwithNeu5Ac2en (PDBcode4YW3, yellow). Thedashed lines in the
corresponding color represent hydrogen-bonding interactions. b, a sche-
matic representation of the interactions between OC and the NanC active
site. The green line represents a hydrophobic surface.
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NanB or NanC (28). The manner of OC to NanC binding is
similar to that of the previously solved NanAOC complex (51).
In particular, the OC 4-amino group forms hydrogen bonds
withAsp-372, and repulsion byArg-351 causes a shift out of the
active site. In the NanA complex, the OC pentyl ether group
forms hydrophobic interactions with Leu-583 and Ile-427 (51).
Conversely, in NanC the pentyl ether group prevents the 396
loop adopting the constricted conformation, because of a steric
clash (Fig. 7a). In comparison with NanA andNanC, the equiv-
alent position in NanB or Neu2 is hydrophilic (24, 25, 56). Cor-
respondingly, OC is a very poor inhibitor of Neu2 (Ki greater
than 6 mM). This is in stark contrast to the low micromolar
inhibition observed for Neu5Ac2en and zanamivir, which can
contribute numerous hydrogen bonding interactions to the
pocket via the C6 glycerol groups (31, 56, 74) (PDB ID: 2F0Z).
These variations in protein-ligand interactions highlight the
FIGURE 8. The proposed NanC reaction mechanism. a, production of Neu5Ac2en from 2,3-linked sialosides. b, hydration of Neu5Ac2en to Neu5Ac. As a
comparison, the NanA hydrolytic sialidase mechanism is shown in red at the point it diverges from the NanC mechanism.
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difficulties in translating structure based drug developments
between sialidases, because although the active sites are often
similar, their ability to bind individual inhibitors differs
substantially.
Conclusions—The results described here present a structur-
ally rationalized and novel mechanism for the unusual produc-
tion of Neu5Ac2en by the NanC sialidase and completes the
structural description of pneumococcal sialidase catalysis. The
mechanistic diversity among the three sialidases, NanA, NanB,
andNanC, is achieved through subtle amino acid substitutions,
positional shifts of conserved residues, and active site plasticity;
the active site core is otherwise preserved. These changes hint
at the evolutionary pressure to adapt to environmental niches,
which vary in substrate type and quantity and underline the
importance of the sialidases for bacterial nutrition and success-
ful host cell invasion. In summary, these works highlight the
importance of thorough structural characterization of siali-
dases; although they may appear, superficially, very similar,
they show significant mechanistic diversity.
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